美沙拉嗪联合蒙脱石散治疗溃疡性结肠炎的临床治疗效果

Clinical effect of mesalazine combined with Montmorillonite Powder in treatment of ulcerative colitis

目的探讨美沙拉嗪肠溶片联合蒙脱石散治疗溃疡性结肠炎的临床治疗效果。方法选取2017年1月—2017年12月在江苏省滨海县人民医院治疗的溃疡性结肠炎患者80例作为研究对象,将患者随机分为对照组和观察组,每组各40例。对照组患者给予柳氮磺吡啶肠溶片,8片/次,3次/d,另给予蒙脱石散,将蒙脱石散置入50 mL的温水内,摇匀后服用,1次/d。观察组患者口服美沙拉嗪肠溶片,4次/d,4片/次;联合蒙脱石散,服用方法同对照组。所有患者均接受8周连续治疗。观察两组患者的临床治疗效果及不良反应发生率,并比较两组治疗前后血清样本中肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)的水平。结果治疗后,观察组患者的临床治疗有效率为92.50%,对照组患者的临床治疗有效率为72.50%,两组比较差异具有统计学意义(P<0.05)。治疗前,两组患者的血清TNF-α及IL-6水平相比,差异均无统计学意义;治疗后,两组血清TNF-α、IL-6水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组患者的血清TNF-α及IL-6水平均显著低于对照组,差异具有统计学意义(P<0.05)。观察组患者治疗期间不良反应发生率为12.50%,对照组患者治疗期间不良反应发生率为32.50%,差异具有统计学意义(P<0.05)。结论美沙拉嗪肠溶片联合蒙脱石散治疗溃疡性结肠炎的临床治疗效果较好,安全性较高。

Objective To investigate the clinical treatment effect of Mesalazine Enteric Coated Tablets combined with Montmorillonite Powder in treatment of ulcerative colitis.Methods Patients(80 cases)with ulcerative colitis in Jiangsu Binhai County People’s Hospital from January 2017 to December 2017 were randomly divided into control group and observation group,and each group 40 cases.Patients in the control group was given Sulfasalazine Enteric-coated Tablets,8 tablets/time,three times daily.And Montmorillonite Powder was put into 50 mL warm water,shaken and taken once a day.Patients in the observation group were given Mesalazine Enteric Coated Tablets,4 tablets/time,four times daily,and combined with Montmorillonite Powder.Patients in two groups were treated for 8 weeks.The clinical effect and the incidence of the adverse reaction of two groups were observed,and the levels of TNF-αand IL-6 before and after treatment were compared.Results After treatment,the effective rate of clinical effect in the observation group was 92.50%,and the effective rate of clinical effect of the control group was 72.50%,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in serum TNF-αand IL-6 of the two groups.After treatment,the levels of TNF-αand IL-6 in two groups were significantly decreased,and the difference was statistically significant in the same group(P<0.05).And the levels of TNF-αand IL-6 in the observation group was significantly lower than those in the control group,with significant difference between two groups(P<0.05).The adverse reaction duration of therapy of observation group was 12.50%,the incidence of the adverse reaction duration of therapy of control group was 32.50%,the difference was statistically significant(P<0.05).Conclusion Mesalazine Enteric Coated Tablets combined with Montmorillonite Powder has good effect in treatment of ulcerative colitis,and the safety is high.